Literature DB >> 27349414

Diagnostic Performance of a Novel Three-Dimensional Neuroretinal Rim Parameter for Glaucoma Using High-Density Volume Scans.

Eric Shieh1, Ramon Lee1, Christian Que2, Vivek Srinivasan2, Rong Guo3, Regina DeLuna4, Sumir Pandit1, Huseyin Simavli2, Rajini Seevaratnam5, Edem Tsikata2, Johannes de Boer6, Teresa C Chen7.   

Abstract

PURPOSE: To evaluate the diagnostic performance of a 3-dimensional (3D) neuroretinal rim parameter, the minimum distance band (MDB), using optical coherence tomography (OCT) high-density volume scans for open-angle glaucoma.
DESIGN: Reliability analysis.
METHODS: setting: Institutional. STUDY POPULATION: Total of 163 patients (105 glaucoma and 58 healthy subjects). OBSERVATION PROCEDURES: One eye of each patient was included. MDB and retinal nerve fiber layer (RNFL) thickness values were determined for 4 quadrants and 4 sectors using a spectral-domain OCT device. MAIN OUTCOME MEASURES: Area under the receiver operating characteristic curve (AUROC) values, sensitivities, specificities, and positive and negative predictive values.
RESULTS: The best AUROC values of 3D MDB thickness for glaucoma and early glaucoma were for the overall globe (0.969, 0.952), followed by the inferior quadrant (0.966, 0.949) and inferior-temporal sector (0.966, 0.944), and then followed by the superior-temporal sector (0.964, 0.932) and superior quadrant (0.962, 0.924). All 3D MDB thickness AUROC values were higher than those of 2D RNFL thickness. Pairwise comparisons showed that the diagnostic performance of the 3D MDB parameter was significantly better than 2D RNFL thickness only for the nasal quadrant and inferior-nasal and superior-nasal sectors (P = .023-.049). Combining 3D MDB with 2D RNFL parameters provided significantly better diagnostic performance (AUROC 0.984) than most single MDB parameters and all single RNFL parameters.
CONCLUSIONS: Compared with the 2D RNFL thickness parameter, the 3D MDB neuroretinal rim thickness parameter had uniformly equal or better diagnostic performance for glaucoma in all regions and was significantly better in the nasal region.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27349414     DOI: 10.1016/j.ajo.2016.06.028

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  15 in total

1.  A Comparison of OCT Parameters in Identifying Glaucoma Damage in Eyes Suspected of Having Glaucoma.

Authors:  Brian C Stagg; Felipe A Medeiros
Journal:  Ophthalmol Glaucoma       Date:  2019-11-27

2.  The ISNT Rule: How Often Does It Apply to Disc Photographs and Retinal Nerve Fiber Layer Measurements in the Normal Population?

Authors:  Linda Yi-Chieh Poon; David Solá-Del Valle; Angela V Turalba; Iryna A Falkenstein; Michael Horsley; Julie H Kim; Brian J Song; Hana L Takusagawa; Kaidi Wang; Teresa C Chen
Journal:  Am J Ophthalmol       Date:  2017-09-23       Impact factor: 5.258

3.  Enhanced Diagnostic Capability for Glaucoma of 3-Dimensional Versus 2-Dimensional Neuroretinal Rim Parameters Using Spectral Domain Optical Coherence Tomography.

Authors:  Kenneth C Fan; Edem Tsikata; Ziad Khoueir; Huseyin Simavli; Rong Guo; Regina A de Luna; Sumir Pandit; Christian J Que; Johannes F de Boer; Teresa C Chen
Journal:  J Glaucoma       Date:  2017-05       Impact factor: 2.503

4.  Structure-Function Mapping Using a Three-Dimensional Neuroretinal Rim Parameter Derived From Spectral Domain Optical Coherence Tomography Volume Scans.

Authors:  Ali Riza Cenk Celebi; Elli A Park; Alice Chandra Verticchio Vercellin; Edem Tsikata; Ramon Lee; Eric Shieh; Hussein Antar; Madeline Freeman; Jing Zhang; Christian Que; Huseyin Simavli; Michael McClurkin; Rong Guo; Tobias Elze; Johannes F de Boer; Teresa C Chen
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

5.  Optical coherence tomography for glaucoma diagnosis: An evidence based meta-analysis.

Authors:  Vinay Kansal; James J Armstrong; Robert Pintwala; Cindy Hutnik
Journal:  PLoS One       Date:  2018-01-04       Impact factor: 3.240

6.  Effects of Age, Race, and Ethnicity on the Optic Nerve and Peripapillary Region Using Spectral-Domain OCT 3D Volume Scans.

Authors:  Linda Yi-Chieh Poon; Hussein Antar; Edem Tsikata; Rong Guo; Georgia Papadogeorgou; Madeline Freeman; Ziad Khoueir; Ramon Lee; Eric Shieh; Huseyin Simavli; Christian John Que; Johannes F de Boer; Teresa C Chen
Journal:  Transl Vis Sci Technol       Date:  2018-11-27       Impact factor: 3.283

7.  Diagnostic Capability of 3D Peripapillary Retinal Volume for Glaucoma Using Optical Coherence Tomography Customized Software.

Authors:  Yingna Liu; Firas Jassim; Boy Braaf; Ziad Khoueir; Linda Yi-Chieh Poon; Geulah S Ben-David; Georgia Papadogeorgou; Edem Tsikata; Huseyin Simavli; Christian Que; Ramon Lee; Eric Shieh; Benjamin J Vakoc; Brett E Bouma; Johannes F de Boer; Teresa C Chen
Journal:  J Glaucoma       Date:  2019-08       Impact factor: 2.503

8.  Analysis of Neuroretinal Rim by Age, Race, and Sex Using High-Density 3-Dimensional Spectral-Domain Optical Coherence Tomography.

Authors:  Hussein Antar; Edem Tsikata; Kitiya Ratanawongphaibul; Jing Zhang; Eric Shieh; Ramon Lee; Madeline Freeman; Georgia Papadogeorgou; Huseyin Simavli; Christian Que; Alice C Verticchio Vercellin; Ziad Khoueir; Johannes F de Boer; Teresa C Chen
Journal:  J Glaucoma       Date:  2019-11       Impact factor: 2.503

Review 9.  Utility of combining spectral domain optical coherence tomography structural parameters for the diagnosis of early Glaucoma: a mini-review.

Authors:  Jean-Claude Mwanza; Joshua L Warren; Donald L Budenz
Journal:  Eye Vis (Lond)       Date:  2018-04-15

10.  Three-dimensional Neuroretinal Rim Thickness and Visual Fields in Glaucoma: A Broken-stick Model.

Authors:  Wendy W Liu; Michael McClurkin; Edem Tsikata; Pui-Chuen Hui; Tobias Elze; Ali R C Celebi; Ziad Khoueir; Ramon Lee; Eric Shieh; Huseyin Simavli; Christian Que; Rong Guo; Johannes de Boer; Teresa C Chen
Journal:  J Glaucoma       Date:  2020-10       Impact factor: 2.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.